HomeCompareBLHEY vs JNJ

BLHEY vs JNJ: Dividend Comparison 2026

BLHEY yields 109.75% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLHEY wins by $19927.63M in total portfolio value
10 years
BLHEY
BLHEY
● Live price
109.75%
Share price
$23.50
Annual div
$25.79
5Y div CAGR
27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19927.66M
Annual income
$17,228,876,736.32
Full BLHEY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BLHEY vs JNJ

📍 BLHEY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLHEYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLHEY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLHEY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLHEY
Annual income on $10K today (after 15% tax)
$9,329.09/yr
After 10yr DRIP, annual income (after tax)
$14,644,545,225.87/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BLHEY beats the other by $14,644,541,239.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLHEY + JNJ for your $10,000?

BLHEY: 50%JNJ: 50%
100% JNJ50/50100% BLHEY
Portfolio after 10yr
$9963.84M
Annual income
$8,614,440,712.86/yr
Blended yield
86.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BLHEY
No analyst data
Altman Z
0.3
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLHEY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLHEYJNJ
Forward yield109.75%2.13%
Annual dividend / share$25.79$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR27.6%28%
Portfolio after 10y$19927.66M$30.3K
Annual income after 10y$17,228,876,736.32$4,689.40
Total dividends collected$19719.56M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BLHEY vs JNJ ($10,000, DRIP)

YearBLHEY PortfolioBLHEY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$24,705$14,004.62$10,592$272.30+$14.1KBLHEY
2$67,693$41,258.76$11,289$357.73+$56.4KBLHEY
3$207,249$134,817.68$12,123$472.89+$195.1KBLHEY
4$713,982$492,225.44$13,141$629.86+$700.8KBLHEY
5$2,786,169$2,022,208.29$14,408$846.81+$2.77MBLHEY
6$12,391,709$9,410,508.67$16,021$1,151.60+$12.38MBLHEY
7$63,170,993$49,911,864.57$18,122$1,588.22+$63.15MBLHEY
8$371,022,031$303,429,068.28$20,930$2,228.20+$371.00MBLHEY
9$2,522,224,231$2,125,230,657.72$24,792$3,191.91+$2522.20MBLHEY
10$19,927,656,664$17,228,876,736.32$30,274$4,689.40+$19927.63MBLHEY

BLHEY vs JNJ: Complete Analysis 2026

BLHEYStock

Bâloise Holding AG, together with its subsidiaries, primarily engages in the insurance and banking businesses in Switzerland, Germany, Belgium, Luxembourg. It operates through Non-Life, Life, Asset Management & Banking, and Other Activities segments. The company offers various non-life insurance products, including accident, health, general liability, motor, fire and other property, marine, credit protection, and legal expenses insurance. It also provides life insurance products, which include endowment policies, such as conventional and unit-linked life insurance; group life insurance products; term insurance; immediate and deferred annuities; and policy riders, including premium waiver, accidental death, and disability. In addition, the company operates Baloise Bank SoBa, a bank in Switzerland; and offers asset management services. Further, it has interests in equity investment companies, real-estate firms, and financing companies. The company sells its products and services to individuals, small and medium sized enterprises, and industrial clients. Bâloise Holding AG was founded in 1863 and is headquartered in Basel, Switzerland.

Full BLHEY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BLHEY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLHEY vs SCHDBLHEY vs JEPIBLHEY vs OBLHEY vs KOBLHEY vs MAINBLHEY vs ABBVBLHEY vs MRKBLHEY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.